DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for heterotaxy, visceral, 1, X-linked — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHeterotaxy, visceral, 1, X-linked maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for heterotaxy, visceral, 1, x-linked is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Heterotaxy syndrome is an uncommon congenital condition with an incidence between 1 in 6000 and 1 in 20,000 live births. It is defined by major cardiac vascular malformations, congenital asplenia or polysplenia, and abnormal arrangement of chest and abdominal organs. One 2020 case report describes an asymptomatic elderly female with multiple accessory spleens, a right-sided stomach, midline liver, azygos continuation of the inferior vena cava, and intestinal malrotation. A 2022 report presents a rare variant that could not be stratified into any existing subset of heterotaxy syndromes. Radiological investigations including radiographs, sonography, and computed tomography are used to correlate clinical symptoms with the extent of thoracic or visceral situs abnormalities.
A 2024 commentary discusses the difficulty of publishing case reports and the ongoing debate over the term "heterotaxy." The authors of a brief report in the same journal conclude that while the atrial appendages may be the only truly isomeric structures, heterotaxy refers to departure from the normal arrangement of any thoracic or abdominal visceral structure, and that a complete description of individual anatomical abnormalities can remove diagnostic ambiguity. A separate commentary by Dr. Bill Evans argues that "heterotaxy" does not define a specific situs or syndrome, meaning only "different arrangement" and nothing more. He states that organ morphology and position do not define situs; rather, they result from it.
The commentary author supports Evans's concepts but notes that Evans misinterprets the rule about using atrial appendage morphology as the starting point for cardiac sequential diagnosis. The author emphasises that atrial morphology as defined by the appendage does not always follow the remainder of the situses, and that such divergence can be catered for by describing the arrangement of different systems separately. Evans wishes to prioritise the arrangement of abdominal great vessels at the level of the diaphragm, but the commentary author counters that this rule is also not inviolable, and that if atrial appendages can now be identified clinically, there is no reason to seek surrogates that are themselves liable to divergence.
No drug, treatment, or intervention is mentioned in any of these abstracts. What is still missing is any clinical trial, any therapeutic strategy, any patient stratification beyond anatomical description, and any funding for research into treatment rather than classification.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Marine Medical Society · 2022 · 0 citations · open access
Heterotaxy
AbstractHeterotaxy syndrome is an uncommon disease, with an incidence ranging from 1 in 6000 to 1 in 20,000 live births. [1] This syndrome is characterized by major cardiac vascular malformations, congenital asplenia, polysplenia, and abnormal arrangement of the chest and abdominal organs. Radiological investigations such as radiographs, sonography, and computed tomography scan play a pivotal role in ascertaining the correlation between clinical symptoms of the patient and the extent of anatomical aberration in the form of thoracic or visceral “situs” abnormalities. The case in this report is a rare variant of heterotaxy, which cannot be stratified into any of the existing subsets for heterotaxy syndromes. The relevant investigations thereof and their relevant findings have been discussed in detail.
DOAJ (DOAJ: Directory of Open Access Journals) · 2020 · 0 citations · open access
Heterotaxy syndrome and interrupted inferior vena cava (IVC) with azygos continuation
AbstractHeterotaxy syndrome or situs ambiguous is a rare congenital disease in which the pattern of anatomical organization of the thoraco-abdominal visceral and vascular structures is not arranged in normal position. Patients with heterotaxy syndrome represent a wide range of anatomical variations including thoraco-abdominal structures. Here we report a rare case of asymptomatic heterotaxy syndrome in an elderly female with multiple accessory spleens, stomach on right side of the abdomen, midline liver, azygos continuation of Inferior Vena Cava (IVC) and intestinal malrotation.
Annals of Pediatric Cardiology · 2024 · 0 citations · open access
The arrangement of the organs
AbstractIn this day and age, it can be difficult to publish the humble case report. And oftentimes, little notice is taken of accounts of such solitary cases once they have been published. Annals are to be applauded, therefore, in publishing the account that describes the unusual finding of absence of the spleen when there is isomerism of both the morphologically left bronchi and the morphologically left atrial appendages.[1] My good friend and colleague Bill Evans, from Nevada, will be delighted to note that the authors conclude their brief account by stating, “While the atrial appendages are the only structures that may be truly isomeric, heterotaxy refers to the departure from the normal arrangement of any thoracic or abdominal visceral structure. A complete description of the individual anatomical abnormalities can remove the ambiguity in the diagnosis.” This is very much in keeping with the recent commentary published by Bill. In his own short work,[2] which very much complements the account to be found in this issue of the journal,[1] Bill expresses in no uncertain terms his own disquiet with the use of “heterotaxy.” To use his own words, “Regarding heterotaxy, the term does not define a specific situs or a syndrome; rather, heterotaxy means ‘different arrangement’ and nothing more.” There is, however, a sting in the tail of Bill’s commentary. He concludes by stating that he anticipates that his commentary will not sit well with some since he tends to diverge from “canon.”[2] He cites three references to support his divergence. As the only author common to all three references is me, it would seem that he anticipates that his conclusions will not sit well with me. This commentary, therefore, gives me the opportunity not only to applaud the authors of the brief report published in this issue, namely Adhikari et al., who work in Thiruvanathapuram, but also to state my support for the concepts espoused by Bill. I would not use the same words, but we are all singing from the same hymn sheet. The key passage in the commentary offered by Dr. Evans is where he comments that “organ morphology and position do not define situs; rather, they result from it.”[2] This is where the words become important since “situs” is no more than the Latin word for “arrangement.” And, as Adhikari et al. have stated,[1] it is by describing separately the arrangements of the different organs that it is possible to remove any potential for ambiguity. As the group working in Thiruvanathapuram also demonstrates, when using modern-day techniques, in particular computed tomography, it is increasingly feasible to diagnose the specific arrangement of the atrial arrangements based on the extent of the pectinate muscles relative to the atrioventricular junctions.[3] This is where Dr. Evans himself does not so much diverge from “canon” but rather misinterprets the rule as we have presented it. From the outset, we have done no more than to suggest that the starting point of cardiac sequential diagnosis should be the identification of atrial morphology, for this purpose, using the most regular atrial feature, which is the appendage. We recognize fully that atrial morphology, as thus defined, does not always follow the remainder of the “situses.” To emphasize again, such divergence, as stated by Adhikari et al.,[1] can be catered for simply by describing the arrangement of the different systems. Dr. Evans wishes to put priority on the arrangement of the abdominal great vessels at the level of the diaphragm. This is a useful guide,[4] but this “rule” is also not inviolable. If we can now identify the atrial appendages in the clinical setting[5] and use this information as the starting point of sequential analysis, why should we seek for surrogates that are themselves liable to divergence?
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
